Aug 30,2018

Novartis, Healint study uses self tracking app to examine migraine, mental health connection

A recent presentation by headache-focused digital health company Healint and pharma giant Novartis employed Healint’s migraine tracking app Migraine Buddy to look at how migraines interact with anxiety and depression. The research found that chronic migraines may induce anxiety and depression instead of the other way around, contradicting previous thought. Authors of the study found that 43 percent of users in the sample suffered from anxiety or depression during a migraine attack (37 percent reporting anxiety and 20 percent reporting depression). The results also show that half of the patients with 15 or more migraine days a month reported anxiety or depression, compared to 34 percent of patients with less than four migraine days.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 04,2018

Positive outcomes from WellDoc's BlueStar translate to cost savings, analysis finds

An analysis contracted by WellDoc found that the company’s digital therapeutic for Type 2 diabetes management could lead to an average savings of more than $250 per patient per month. WellDoc’s FDA-cleared, reimburseable BlueStar system for diabetes management analyzes patient data, compares the data to past trends, and sends analytics to the patient’s healthcare team. The app-driven program also features behavioral coaching, motivational messages, educational content, and other tools for population health analysis.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 24,2018

Propeller publishes paper showing improvements in asthma symptoms and control

Propeller Health studied the impact of Propeller on a group of 95 participants from Louisville during the pilot phase of our work with the city. Research found that people showed consistent and sustained improvements in asthma outcomes over the 13-month study period, including more than 39% fewer rescue inhaler uses, 23% more symptom-free days, and improved asthma control.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 15,2018

FareWell changes name to Better Therapeutics, sees 0.8 percent A1c reduction in small study

San Francisco-based FareWell is changing its name to Better Therapeutics, a rebranding that reflects the company’s shift in focus from weight loss and disease prevention to digital therapeutics to treat chronic diseases. To punctuate that shift, Better Therapeutics is announcing the name change on the same day as the publication of a study in the Journal of Medical Internet Research that demonstrates the company’s technology can reduce HbA1c in people with Type 2 diabetes. The nonrandomized study included 118 individuals with Type 2 diabetes, recruited primarily via Facebook ads. They used Better Therapeutic’s app-based platform, which also included phone calls with health coaches, for 12 weeks. Participants interacted with the app an average of 4.3 times a day and more than 86 percent stuck with the app for the full 12 weeks. Those who were more engaged also tended to have better outcomes.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 20,2018

Research overview: Findings shared at the 2018 American Academy of Allergy, Asthma, and Immunology Conference

Earlier this month, Propeller Health attended the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization Joint Conference in Orlando, FL. The conference highlights key advancements in research through symposiums and poster sessions. Propeller, in collaboration with the Children’s Hospital Colorado, presented inhaler sensor data that assessed patterns of rescue and controller medication use among children and adults with self-reported persistent asthma. Using sensor data from almost 1,400 patients, the company observed rates of controller inhaler adherence by age, time of day, and season. Propeller Health found that adolescents and young adults had lower rates of adherence compared to older adults who demonstrated improved adherence with increasing age.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Apr 13,2018

One Drop Direct-to-Consumer Subscriptions Lower A1c by 1.9% in 3 Months

One Drop's direct-to-consumer digital therapeutics solution lowers estimated A1c (eA1c) in people with type 2 diabetes by 1.90% in just 3 months. These findings were published in two peer-reviewed retrospective studies presented at the 39th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine (SBM). The company has released over a dozen peer-reviewed studies on the efficacy of its mobile app and coaching service respectively, but these most recent analyses are the first to examine One Drop’s fully integrated solution.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
May 29,2018

Study: Smartphone app effective in treating serious mental illness

A recent study published by Psychiatric Services found that mobile health interventions were as effective in treating patients with serious mental illness compared to an in-person group therapy. The study found that participants in the mobile health group were more likely to remain fully engaged in the eight-week study than those receiving traditional care. Researchers also found that satisfaction rates between the two groups were similar, and that the conditions of participants in both groups improved significantly.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 06,2018

Click Therapeutics Announces Multiple Publications Supporting Its Digital Therapeutic for Major Depressive Disorder

Click Therapeutics announces today multiple publications and presentations of clinical research data supporting its digital therapeutic for major depressive disorder (MDD). The results of a 51-person randomized controlled trial of the Emotional Faces Memory Task (EFMT), a digital therapeutic for MDD, were recently published in npj Digital Medicine, a Nature research journal. This trial found EFMT to be superior to the control group in terms of MDD symptom reduction, and also the proportion of participants meeting “clinical responder” criteria.

CLINICAL STUDY

#software

#pdt

View Analyst & Ambassador Comments
Go to original news
Jun 27,2018

How Digital Health Interventions are Changing the One-Size-Fits-All Approach to Asthma Treatment

The symptoms of asthma may vary dramatically from patient to patient. Age of onset, triggers and mechanism of disease are factors that also influence the symptoms of asthma, the way the disease is expressed and its severity. Propeller Health recently partnered with research scientists from Children’s Hospital Colorado to better understand two of the most challenging complexities of asthma: medication adherence and the assessment of asthma control.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Jun 27,2018

Quest, Omada Health Collaboration Shows One-Third in Workforce Study Reduced Risk for Diabetes

A study presented Monday at the American Diabetes Association (ADA) Scientific Sessions found that one-third of those who initially screened positive for prediabetes or diabetes were able to bring their blood sugar down to normal levels after taking part in a workforce-based intervention. The study by Quest Diagnostics, which involved a collaboration with the digital health provider Omada Health, shows promise for employer-based wellness programs that involve a 2-step process: screening for those at risk, and then offering an evidence-based program of lifestyle change and support for those whose health risks are revealed during screening.

CLINICAL STUDY

#cbt

#coaching

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY